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AML-1AandAML-1B regulation of MIP-1expression in multiple myeloma
Sun J. Choi, Tomoko Oba, Natalie S. Callander, Diane F. Jelinek, and G. David Roodman
Macrophage inﬂammatory protein-1 (MIP-
1) is produced in high concentration by
multiple myeloma (MM) cells in about 70%
of patients, and MIP-1 levels correlate with
their disease activity. Patients who have
high levels of MIP-1 have a poor progno-
sis. Furthermore, blocking MIP-1 expres-
sion in an in vivo model of human MM
profoundly decreases both tumor burden
and bone destruction, suggesting that
MIP-1isanimportantmediatorofMMbone
disease.Therefore,toanalyzetheregulation
of MIP-1 production in MM, we cloned the
human MIP-1 promoter and characterized
the transcription factor (TF) motifs that con-
trol MIP-1 expression in MM cells. The
proximal region of MIP-1 promoter was
composed of 2 sets of identical transcrip-
tion regulatory regions consisting of
GATA-2 AML-1 C/EBP motifs. Since 2
alternatively spliced variants of the acute
myeloid leukemia-1 (AML-1) class of TFs
can bind the AML-1 region, AML-1A and
AML-1B, the relationship between the ex-
pression levels ofAML-1AorAML-1B in MM
cells and their capacity to express MIP-1
was examined. AML-1A mRNA was rela-
tivelyoverexpressedcomparedwithAML-1B
in MM cell lines that produced high levels of
MIP-1 (> 1 ng/mL per 106 cells per 72
hours), but AML-1A was not increased in
MM cell lines that expressed less than 200
pg/mL MIP-1. More importantly, the ratio of
AML-1A to AML-1B mRNA levels was also
increased in 3 of 3 highly puriﬁed myeloma
cells from patients with MM who expressed
increased amounts of MIP-1. The ratio of
AML-1A to AML-1B mRNA in patients with
MM was 8-fold higher than in healthy con-
trols. Transduction of AML-1B into the MM-
derived MM.1S and ARH-77 cells totally
blocked MIP-1 production, while AML-1A
did not further increase the already high
levels of MIP-1 produced by these cells.
Taken together, these data demonstrate that
in patients with MM who produce increased
concentrations of MIP-1, the relative level
of AML-1B is signiﬁcantly decreased com-
pared with healthy controls. The data sug-
gest that strategies that enhance AML-1B
expression or decreaseAML-1Ain MM cells
may be beneﬁcial therapeutically. (Blood.
2003;101:3778-3783)
© 2003 by TheAmerican Society of Hematology
Introduction
Multiple myeloma (MM) is an incurable plasma cell neoplasm that
accounts for 13% of all hematologic malignancies.1,2 Bone destruc-
tion is a common manifestation of the disease and is a major source
of morbidity for the patients. Bone destruction results from highly
localized osteoclastic bone resorption that is induced by an
osteoclastic stimulatory factor(s) secreted by MM cells and/or
marrow stromal cells adjacent to the myeloma cells.3 In vitro
studies have implicated several cytokines as potential factors
responsible for the bone destruction in MM, including interleukin 1
beta (IL-1), IL-6, and lymphotoxin. However, none of these
cytokines has been found to be consistently elevated in peripheral
blood or bone marrow plasma of patients with MM.4,5 Receptor
activator of nuclear factor–kappa B ligand (RANKL), a recently
described osteoclastogenic factor, has been shown to be up-
regulated in bone marrow samples from patients with MM. In
addition, blocking RANKL activity with osteoprotegerin or a
soluble form of the RANK receptor (RANK-Fc) decreased the
bone destruction in an in vivo model of myeloma.6-8 These data
demonstrated an important role for RANKLin the bone destruction
in myeloma.
We have used an expression cloning approach with a human MM
patient–derived cDNA expression library to screen for osteoclast-
inducing factors produced by MM cells, and identiﬁed macrophage
inﬂammatory protein-1 (MIP-1) as an osteoclastogenic factor pro-
duced by MM cells from patients with the disease. MIP-1 levels in
bone marrow plasma from patients with MM correlated with their
disease activity.9 Furthermore, we found that MIP-1 in addition to
being a potent osteoclastogenic factor, also enhanced the effects of
RANKL on human osteoclast (OCL) formation.10 Studies with an in
vivo model of MM, in which severe combined immunodeﬁciency
(SCID) mice received transplants of the human MM-derived ARH-77
cells,11 demonstrated that when SCID mice received transplants of
ARH-77 cells stably transfected with an antisense construct to MIP-1
(AS-ARH), the AS-ARH mice lived longer than control mice and had
no radiologically identiﬁable lytic lesions. Histomorphometric analysis
demonstrated that the number of OCLs and the percent of tumor cells
per bone area for mice that underwent transplantation with AS-ARH
cells were signiﬁcantly less than control mice that underwent transplan-
tation with ARH-77 cells transfected with the empty vector. Blocking
MIP-1activity inhibited both MM cells homing to the marrow as well
as tumor growth. Taken together, these data demonstrated that blocking
MIP-1 activity has profound effects on the tumor burden and bone
destruction in this in vivo model of MM, and suggest that blocking
MIP-1 expression and activity in patients with MM could have a
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3778 BLOOD, 15 MAY 2003 VOLUME 101, NUMBER 10signiﬁcant therapeutic beneﬁt. Therefore, to identify the factors control-
lingMIP-1expression,wehaveusedpromoteranalysistocharacterize
the transcription factors (TFs) that regulate the MIP-1 expression in
MM cells. We report that the AML-1 class of TFs, AML-1A and
AML-1B, regulate MIP-1expression, and that abnormal expression of
these TFs in MM cell lines and bone marrow cells from patients with
MM correlates with increased MIP-1expression.
Patients, materials, and methods
Cell culture and bone marrow samples from patients
with multiple myeloma
Human ARH-77, THP-1, HL-60, Reh, and U937 cells were purchased from
American Type Culture Collection (ATCC, Rockville, MD). KAS6/1 and
MCQ/2 MM cell lines were obtained from Dr D. F. Jelinek (Mayo Clinic,
Rochester, MN), and the MM.1S12 MM cell line was kindly provided by Dr S.T.
Rosen (Northwestern University, Chicago, IL). These cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine serum. Bone marrow
aspirates were collected into heparinized syringes from patients with MM
(Durie-Salmon, stages I-III), and healthy controls. All patients gave informed
consent prior to obtaining these samples. These studies were approved by the
institutional review board of the University of Pittsburgh.
The bone marrow was pelleted by centrifugation at 1000g at 4°C
immediately after collection, and the bone marrow plasma was collected
and stored at 80°C for subsequent studies. The cells were resuspended in
–minimal essential media (MEM)/5% fetal calf serum (FCS), and the
mononuclear cell fraction was separated by gradient centrifugation.
Isolation of primary myeloma cells from patients
with multiple myeloma
Patient bone marrow–derived myeloma cells were puriﬁed by CD138
(syndecan-1) microbeads using a Miltenyi magnetic cell sorting system
(Miltenyi Biotec,Auburn, CA) as described by Draube et al.13 Brieﬂy, bone
marrow mononuclear cells (108) were incubated with CD138 microbeads
for 15 minutes and loaded onto a positive selection column placed in the
magnetic ﬁeld. The column was washed with 1 mL buffer (phosphate-
buffered saline [PBS] containing 0.5% bovine serum albumin [BSA] and 2
mM EDTA [ethylenediaminetetraacetic acid]) 3 times. After removing the
column from the magnetic ﬁeld, CD138 cells were eluted with 1 mLbuffer
using a plunger and washed with PBS 2 times. The purity of the myeloma
cells exceeded 98% as assessed by CD138/CD45 staining and morphology.
Cloning of the human MIP-1 promoter
The human MIP-1 cDNA (1.1 kb)14 was used as a probe for bio-
informatics screening of the The National Center for Biotechnology
Information (NCBI) human genomic database for the MIP-1 promoter. A
2-kb MIP-1 promoter sequence was identiﬁed in a MIP-1–containing
bacterial artiﬁcial chromosome (BAC) clone. The BAC clone (accession
numberAC003976) containing the MIP-1 promoter was then subjected to
further analysis. Ampliﬁed genomic DNA (130 kb to 170 kb insert) in the
BAC clone was digested with restriction enzymes EcoRI, SstI, and XbaI
and analyzed by 0.6% agarose gel electrophoresis. The gel was stained with
ethidium bromide, transferred to a nitrocellulose membrane, and Southern
blot analysis was performed using a 32P-labeled MIP-1 cDNA probe (5,
380 bp). A 4.2-kb genomic DNA fragment that was digested with EcoRI
was hybridized with the MIP-1 cDNAprobe. The 4.2-kb EcoRI band was
transferred into the pBS KSII (Stratagene, La Jolla, CA) vector for
further analysis.
Generation of human MIP-1 promoter luciferase reporter
constructs and their truncated forms
The 4.2-kb MIP-1 promoter genomic DNA was subjected to DNA
sequence analysis to conﬁrm its identity. The 2-kb genomic DNAfragment
was digested with SstI and XhoI and subcloned into the luciferase reporter
vector, pGL2Enh (Promega, Madison, WI) (pGL2E-MIP). Truncated forms
of the MIP-1 promoter reporter construct were generated with the
Erase-A-Base system (Promega). Brieﬂy, the full-length construct was
digested ﬁrst with KpnI, resulting in a fragment that could not be degraded
by Exonuclease III, and then was digested by MscI, which resulted in a
fragment that could be easily degraded by Exonuclease III. The reaction
time of the Exonuclease III digestion was adjusted to generate the different
truncated forms of the MIP-1 promoter insert.After blunt end generation,
self-ligation was performed and the ligation product was transformed into
E coli–competent cells. Clones of different insert sizes for the MIP-1
promoter were isolated, and the exact promoter location was conﬁrmed by
DNAsequence analysis using a GL1 primer.
Transfection of MIP-1 promoter luciferase reporter constructs
and assay for promoter activity
Full-length and truncated MIP-1 promoter constructs were transfected into
MM.1S cells, ARH-77 cells, human monocytic cells (HL-60, U937, THP-1),
normal human B cells (Reh), or 293 cells using a Lipofectamine Plus kit
(Invitrogen, Carlsbad, CA) with minor modiﬁcation. Brieﬂy, MM.1S, ARH-77,
U937, Reh, THP-1, and HL-60 cells (106/well) were cultured in 6-well plates
with serum and antibiotic-free RPMI 1640 media. After 3 hours, MIP-1
promoterconstructDNAs(1g)andRenillaluciferaseDNA(1g)werediluted
with 100 g serum and antibiotic-free Dulbecco modiﬁed Eagle medium
(DMEM), and then 6 g PLUS reagent was added. pTK Renilla luciferase was
cotransfected as an internal control as described.15 After 15 minutes of incuba-
tion, lipofectamine (4 g) diluted with 100 g serum and antibiotic-free DMEM
(Invitrogen) was added and the reaction was incubated for another 15 minutes.
Transfection reagents were added to cells in 6-well plates with serum and
antibiotic-free RPMI 1640 media (Invitrogen). After 6 hours, complete media
that contained serum and antibiotics were added, and after 72 hours of incubation
in5%CO2at37°C,theluciferaseactivitywasassayedwithaluminometer.Atthe
end of the culture period, cells were harvested, washed with PBS, and suspended
in passive lysis buffer (Promega). Clear cell lysates were harvested by microcen-
trifugation,andFireﬂyandRenillaluciferaseactivityweremeasuredusingadual
luciferase assay system (Promega). The relative activity (ratio between Fireﬂy
and Renilla luciferase activity) was calculated, and ratios that were at least 5-fold
higher than baseline were considered signiﬁcant. In selected experiments,
AML-1A and AML-1B cDNAs were inserted into the mammalian expression
vector pcDNA3 and cotransfected into ARH-77 and MM.1S cells, to test the
modulatory effects of theseTFs on MIP-1promoter activity.
Identiﬁcation of the putative transcription factors that may
regulate MIP-1 expression and cloning of the AML-1A
and 1B cDNAs
The DNA sequence of the MIP-1 promoter (671 bp to 45 bp) was
analyzed for putative transcriptional regulatory factors using a transcription
factor search program, TFSITE (http://www.cbrc.jp/research/db/
tﬁsearch.html). To determine the transcriptional modulatory effects of the
AML-1 class of TFs on the MIP-1 expression, we identiﬁed expressed
sequence tag (EST) clones (accession numbers AI911291 and AL559418)
that contain full-length AML-1A and AML-1B cDNA and obtained these
EST clones from IMAGE Consortium (National Institutes of Health,
Bethesda, MD). They were subcloned into the mammalian expression
vector (pcDNA3) and subjected to sequence analysis.
RT-PCR analysis of AML-1A and AML-1B mRNA expression
in MM cells and patients with MM
To determine mRNAexpression levels of MIP-1,AML-1A, andAML-1B
in MM cells and bone marrow cells from patients with MM compared with
healthy controls, we performed reverse transcriptase–polymerase chain
reaction (RT-PCR) analysis using AML-1A, AML-1B, MIP-1, and
glyceraldehyde phosphate dehydrogenase (GAPDH) speciﬁc primer sets.
Total RNA from bone marrow cells from patients and healthy donors were
isolated with Trizol reagent (Invitrogen). RNA was precipitated with
isopropanol, and the pellets were washed with 70% ethanol, brieﬂy air
dried, dissolved in diethylpyrocarbonate-treated water, and stored at
80°C. The primer sequences for the RT-PCR analysis were 5-CTG GTC
ACT GTG ATG GCT GG-3 (AML-1A sense strand [SS]), 5-CTG CCT
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CGACAG CCC CAACTTCC-3 (AML-1B SS), 5-AGGTGG CGACTT
GCG GTG GG-3 (AML-1B AS), 5-ACA TTC CGT CAC CTG CTC
AG-3 (MIP-1 SS), 5-CGG TTG TCA CCA GAC GCG G-3 (MIP-1
AS), 5-ACCACAGTC CAT GCCATCAC-3 (GAPDH SS), and 5-TCC
ACC ACC CTG TTG CTG TA-3 (GAPDH AS). The PCR conditions
typically were 94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1
minute, and 21 to 32 cycles for each target. The PCR product was subjected
to agarose gel analysis, and the bands were scanned and quantiﬁed by
densitometer.
Statistical analysis
Results were compared by a 2-way analysis for repeated measures and were
considered signiﬁcant if P  .05.
Results
Cloning of the human MIP-1 promoter and generation
of deletion constructs
The DNA sequence of the human MIP-1 promoter was identiﬁed
in the NCBI human genome project database and is shown in
Figure 1. A BLAST search using the MIP-1 promoter sequence
was used to identify a BAC clone that contained the MIP-1
promoter. A 4.2-kb genomic DNA fragment was identiﬁed by
hybridization with a MIP-1 cDNAprobe (Figure 2) and truncated
forms of the MIP-1 promoter generated as described in “Patients,
materials, and methods” are shown in Figure 3.
MIP-1 promoter activity is enhanced in MM-derived ARH-77
cells, but not in other hematopoietic cell types
To test the various MIP-1 promoter deletion constructs for their
relative activity, full-length (2 kb) or truncated forms of MIP-1
promoter luciferase reporter constructs were transfected into vari-
ous cell types including MM-derived ARH-77 cells. As shown in
Figure 4, the full-length MIP-1 promoter construct dramatically
enhanced basal luciferase activity more than 50-fold in ARH-77
cells compared with the 64-bp basal promoter. Furthermore, the
truncated MIP-1 promoter construct that contained 671 bp of the
MIP-1 promoter increased luciferase activity to similar levels as
the full-length promoter construct. In contrast, luciferase activity
was not signiﬁcantly enhanced when the full-length MIP-1
promoter construct was transfected into nonmyeloma cells such as
HL-60, U937, THP-1, Reh, and 293 cells. These data suggest that
ARH-77 cells express a speciﬁc transcription activator(s) that
up-regulates MIP-1 expression, and that the proximal region (671
bp) of the MIP-1 promoter may be critical for enhanced MIP-1
expression inARH-77 cells.
Cotransfection of AML-1A, but not AML-1B, enhances
MIP-1 promoter activity
The DNAsequence of the MIP-1 promoter (671 bp to 45 bp)
was analyzed for putative transcriptional regulatory regions. The
proximal domain was composed of 2 sets of distinct transcription
regulatory regions (GATA-2 AML-1 C/EBP) between 388
bp to 354 bp and 153 bp to 105 bp (Figure 5). Since the
Figure 1. Genomic sequence of the hMIP-1 promoter. The DNA sequence of a
2-kb hMIP-1 promoter was determined using the NCBI database. EcoRI (1995:
gaattc) and XhoI( 54: ctcgag) sites (in bold) were used for subcloning into luciferase
reporter constructs. Transcriptional starting site (1) and translational starting Met
site (98: atg) were determined by Nakao et al,14 and the MscI site (1275: tggcca)
was used for Erase-A-Base studies.
Figure 2. Southern blot analysis of BAC clone AC003976, which contained the
hMIP-1 promoter. The genomic insert DNA digested with EcoRI, SstI, and XbaI
was hybridized with an hMIP-1 cDNA probe. A 4.2-kb EcoRI band was selected
(arrow) and subjected to further analysis.
Figure 3. Generation of human MIP-1 reporter constructs. Truncated forms of
hMIP-1 promoter were generated from the 2-kb pGL2E-MIP construct by the
Erase-A-Base system and followed by sequence analysis to conﬁrm the 5 end of the
hMIP-1 promoter. These luciferase reporter constructs were transfected into the
various cell lines to assess MIP-1 promoter activity.
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TFs, we determined the modulatory effects of theseTFs on MIP-1
promoter activity. Two major forms of the AML-1 transcription
factors that bind this region, AML-1A and AML-1B, result from
alternative splicing of the AML-1 gene.16,17 Using an EST clone
database search, we identiﬁed and cloned AML-1A and AML-1B
cDNAs that contained the open reading frame into the mammalian
expression vector pcDNA3.
We then cotransfected the AML-1A and AML-1B cDNAs with
either full-length or truncated forms of the hMIP-1 promoter
luciferase construct into ARH-77 and MM.1S cells. As shown in
Figure 6C,F the reporter construct that contained only one AML-1
binding element did not display increased promoter activity in
ARH-77 and MM.1S cells, regardless if the cells were cotrans-
fected withAML-1AorAML-1B. In contrast, cotransfection of the
reporter construct that contained 2 AML-1 binding elements with
theAML-1Aconstruct intoARH-77 and MM.1S cells signiﬁcantly
increased MIP-1 promoter activity compared with the reporter
construct that contains one AML-1 binding site or to control cells
cotransfected with empty vector (EV) (Figure 6B,E). Furthermore,
cotransfection of the full-length luciferase reporter construct with
AML-1A further increased MIP-1 promoter activity (Figure
6A,D). In contrast, AML-1B signiﬁcantly decreased MIP-1
promoter activity about 50% in ARH-77 and MM.1S cells com-
pared with the controls cotransfected with EV, whenAML-1B was
cotransfected with the full-length MIP-1 luciferase construct
(Figure 6A,D). AML-1B did not signiﬁcantly affect the luciferase
activity of the proximal MIP-1 promoter construct that contained
671 bp (Figure 6B,E).
AML-1B but not AML-1A is down-regulated in MM.1S, ARH-77,
and MCQ-2 MM cells and in highly puriﬁed myeloma cells
from patients who have enhanced MIP-1 expression
To study the relationship between the expression levels ofAML-1A
or AML-1B and MIP-1 expression in MM cell lines and patients
with MM compared with healthy controls, the mRNA expression
levels for MIP-1 AML-1A, and AML-1B were determined by
RT-PCR. As shown in Figure 7, mRNA expression levels of
AML-1B were decreased in MM cells that released more than
1 ng/mL MIP-1 into their 72-hour conditioned media (106 cells)
(MM.1S, ARH-77, and MCQ-2), but not in KAS 6/1 and ANBL-6
MM cells, which released less than 200 pg/mL MIP-1. Nonmy-
eloma cells such as HL-60, U937, and THP-1 did not express
MIP-1 or AML-1A mRNA, but expressed easily detectable
amounts ofAML-1B mRNA. Similarly, MIP-1 mRNAexpression
levels were increased 2- to 5-fold in 7 of 10 samples of bone
marrow mononuclear cells from patients with MM and in 3 of 5
samples of CD138 myeloma cells puriﬁed from these patients.
Figure 4. Luciferase activities of the hMIP-1 promoter constructs. The hMIP-1
promoter luciferase reporter constructs were cotransfected with the pTK Renilla
luciferase construct into the various cell lines and relative activities (Fireﬂy/Renilla
luciferase activity) were determined. The promoter construct containing 671 bp of
the MIP-1 promoter signiﬁcantly enhanced luciferase activity in ARH-77 MM cells,
but not in nonmyeloma HL-60, U937, THP-1, Reh, and 293 cells. Similar results were
seen in 2 independent experiments (*P  .05). Error bars indicate SE.
Figure 5. Schematic diagram of transcription factor (TF) response elements
that may regulate MIP-1 expression. The proximal domain of the hMIP-1
promoter was composed of 2 sets of distinct transcription regulatory regions, GATA-2
plusAML-1 plus C/EBP including one TATA box and 2 AP-1 sites.
Figure 6. AML-1A, but not AML-1B, increases hMIP-1 promoter activity. The
MIP-1 promoter constructs were cotransfected with AML-1A and AML-1B cDNAs in
pcDNA3 into ARH-77 (A-C) and MM.1S (D-F) cells, to test the modulating effects of the
AML-1 class ofTFs on MIP-1promoter activity. Cotransfection ofAML-1AorAML-1B with
the luciferase reporter construct (Luc) containing one AML-1 binding motif did not
signiﬁcantly enhance promoter activity. In contrast, cotransfection of the reporter construct
that contained 2 AML-1 binding elements with the AML-1A construct into ARH-77 and
MM.1S cells signiﬁcantly increased MIP-1 promoter activity compared with the empty
vector (EV) control (Figure 6B,E). Furthermore, cotransfection of the full-length luciferase
reporter construct with AML-1A further increased MIP-1 promoter activity (Figure 6A,D).
AML-1B signiﬁcantly decreased full-length MIP-1promoter activity about 50% inARH-77
and MM.1S cells compared with the EV control. Similar results were seen in 3 independent
experiments (*P  .05).
Figure 7. Expression levels of AML-1A and AML-1B mRNA in various cells.
mRNAexpression levels ofAML-1A,AML-1B, and MIP-1were determined in various cell
lines including MM-derived cell types by RT-PCR analysis. Expression levels of AML-1A
mRNA were up-regulated in the MIP-1, producing MM cells (MM.1S, ARH-77, and
MC/Q2). Relative expression levels of AML-1B mRNA were up-regulated in the MM cells
expressing low levels of MIP-1and non-MM hematopoietic cells.
AML-1A/B REGULATION OF MIP-1 EXPRESSION IN MM 3781 BLOOD, 15 MAY 2003 VOLUME 101, NUMBER 10Interestingly, mRNAexpression levels ofAML-1B were decreased
in 5 of 7 samples of bone marrow mononuclear cells from patients
with MM (patients 3, 4, 6, 7, and 9) and 3 of 3 CD138 myeloma
cells from these patients (patients 1 and 3) who expressed increased
levels of MIP-1 mRNA, while AML-1B mRNA was easily
detectable in 7 of 9 bone marrow samples from healthy donors. In
contrast,AML-1AmRNAexpression was detected in 8 of 10 bone
marrow samples from patients with MM, 4 of 5 CD138 myeloma
cells from patients with MM, and 9 of 9 bone marrow samples from
healthy controls (Figure 8A). Calculation of the mRNAexpression
ratios for AML-1A to AML-1B in these subjects showed that the
average ratio of mRNA expression of AML-1A to AML-1B was
8-fold higher in patients with MM than in healthy controls (Figure
8B), and in patients with increased MIP-1 expression (patients 1,
3, 4, 5, 6, 7, and 9), the AML-1A/AML-1B ratio was increased
more than 10-fold (P  .022).
Transduction of AML-1B into ARH-77 or MM.1S MM cells
totally blocks MIP-1 expression
To test the effects ofAML-1AandAML-1B on MIP-1 expression
in MM cells, theAML-1A,AML-1B cDNA, or the empty pcDNA3
vector was stably transfected into theARH-77 and MM.1S cells as
described previously.9After G418 selection, MIP-1 protein levels
were measured using an enzyme-linked immunosorbent assay
(ELISA) kit.As shown in Figure 9, transduction ofAML-1B cDNA
markedly inhibited MIP-1 protein production in ARH-77 (Figure
9A) and MM.1S (Figure 9B) cells ( 200 pg/mL). In contrast,
transduction of the AML-1A cDNA did not further increase the
already high levels of MIP-1 in ARH-77 and MM.1S cells
compared with cells stably transfected with EV (ARH-77, 2 to 3
ng/5 	 106; MM.1S, 6 to 7 ng/5 	 106 cells, cultured for 48 hours).
Discussion
In the present study, we found that human MIP-1 promoter activity is
up-regulated in the MM-derived ARH-77 cell line but not in other
hematopoietic cell types such as THP-1, HL-60, Reh, and U937. These
data suggest that speciﬁc regulatory factor(s) that enhance MIP-1
promoter activity were present in ARH-77 cells. We further demon-
strated that the 671-bp proximal region of hMIP-1 promoter was
responsible for the increased MIP-1 promoter activity. The proximal
region of MIP-1 promoter is composed of 2 sets of distinct transcrip-
tion regulatory domains (GATA-2 AML-1 C/EBP). Since the
AML-1 class of TFs are hematopoietic and bone speciﬁc, and is
expressed in hematopoietic cells at high levels,18-20 we determined the
roles of theseTFs on MIP-1promoter activity and MIP-1production
in MM-derivedARH-77 cells.
TheAML-1 class of TFs occurs in 2 major forms (AML-1Aand
AML-1B) that can bind AML-1 response motifs.17 AML-1A is a
truncated form of AML-1B and lacks a portion of the C-terminal
nuclear matrix targeting domain.21,22 Normally,AML-1B modestly
up-regulates mRNA transcription of hematopoietic genes such as
granulocytecolony-stimulatingfactor(G-CSF),macrophagecolony-
stimulating factor (M-CSF), and IL-3,23 and markedly activates
transcription of these genes to higher levels in collaboration with
other tissue-speciﬁc regulators such as AP-1, C/EBP, ets-1, PU-1,
and c-Myb.24,25 In contrast, AML-1A competitively binds AML-1
response motifs and inhibits AML-1B–dependent transcriptional
activation.26 However, we found that AML-1A increased MIP-1
promoter activity, whereas AML-1B inhibited up-regulation of the
MIP-1 promoter by AML-1A. Interestingly, the MM-derived
ANBL-6 cell that expressed less than 200 pg/mLMIP-1 and other
hematopoietic cell types such as HL-60, U937, and THP-1
expressed only the AML-1B transcript but not the AML-1A
transcript. MM cell lines that produced high levels of MIP-1
(
1 ng/mL) predominantly expressed the AML-1A transcript,
rather than AML-1B. These data demonstrate that AML-1A
enhances MIP-1 promoter activity while AML-1B inhibits the
transcriptional activation of the MIP-1 gene, and suggest that the
Figure 9. Transduction of AML-1B cDNA into ARH-77 and MM.1S cells totally
blocked MIP-1 expression. AML-1A, AML-1B cDNA, or pcDNA3 vector were
stably transfected into the ARH-77 (A) and MM.1S (B) cells and expression levels of
MIP-1 were measured using an ELISAkit. Transduction ofAML-1B cDNAmarkedly
decreased MIP-1 production in ARH-77 and MM.1S cells ( 200 pg/mL) and
transduction of AML-1A cDNA did not signiﬁcantly alter MIP-1 expression. Similar
results were seen in 2 independent experiments (*P  .05).
Figure 8. mRNAexpression levels ofAML-1AandAML-1B in patients with MM versus healthy controls. mRNAexpression levels of MIP-1,AML-1A, andAML-1B were
examined by RT-PCR analysis in total bone marrow cells and puriﬁed CD138 myeloma cells from patients with MM, compared with samples from healthy donors. mRNA
expression levels of MIP-1 were increased in 7 of 10 total bone marrow cells and 3 of 5 CD138 myeloma cells from patients with MM. mRNA expression levels of AML-1B
were decreased in 5 of 7 total bone marrow cells and 2 of 3 myeloma cells from patients with MM who showed increased MIP-1 expression.AML-1AmRNAexpression was
detected in 8 of 10 and 4 of 5 myeloma cells from patients with MM, and 9 of 9 normal samples (A). The ratio of mRNA expression of AML-1A to AML-1B was 8-fold higher in
patients with MM than in healthy controls and was increased more than 10-fold in patients with increased MIP-1 expression, such as in patients 1, 3, 4, 5, 6, 7, and 9
(P  .022) (B). Horizontal bars indicate the average; vertical bars, SE.
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differ depending on the cell type and tissue examined. These
differences may contribute to the tissue-speciﬁc functions of the
AML-1 class of TFs.27,28 Consistent with these observations is our
ﬁnding that the ratios of AML-1A to AML-1B mRNA expression
levels were dramatically increased more than 10-fold in bone
marrow samples from patients with MM who expressed MIP-1.
Furthermore,transductionoftheMM-derivedMM.1SandARH-77
cell lines with AML-1B markedly decreased MIP-1 production.
Surprisingly, transduction of MM.1S and ARH-77 cells with
AML-1Adid not further increase MIP-1 production, even though
it increased MIP-1 promoter activity in these cells. These data
suggest that MIP-1 production by MM.1S and ARH-77 cells is
already maximal, and that transduction and overexpression of
AML-1A does not further enhance MIP-1 production. AML-1B
appears to act as a competitive inhibitor of transcriptional up-
regulation of MIP-1 promoter activity by AML-1A and as a
negative regulator of MIP-1 production.
OtherTFs in addition to theAML-1 class ofTFs may be involved in
the transcriptional regulation of the MIP-1promoter and cooperatively
up-regulate MIP-1promoter activity. Supporting this hypothesis is our
ﬁnding that the 2-kb MIP-1 promoter construct demonstrated en-
hanced promoter activity compared with that of the 671-bp proximal
MIP-1 promoter construct. These data suggest that enhancer ele-
ment(s) are present in the upstream 1.4-kb region of the 671-bp
proximal promoter. Furthermore, cotransfection of AML-1A with core
binding factor beta (CBF), an activation subunit of theAML-1 class of
TFs,29,30 further enhanced MIP-1 promoter activity. In contrast,
cotransfection of AML-1B with CBF did not alter the MIP-1
promoter activity (S.J.C., unpublished data,August 2002).
Patients with increased levels of MIP-1 have a poor prognosis.
However, it is unclear if this is simply due to the elevated
expression levels of MIP-1 or results from the other genes that are
also up-regulated in MM cells producing MIP-1. Abnormal
expression of the AML-1 class of TFs, which results in enhanced
MIP-1 production, also may increase the expression of other
genes that affect MM cell growth, MM cell adhesion to stromal
cells, or their sensitivity to chemotherapy.31-33
We detected both AML-1A and AML-1B mRNA transcripts
by RT-PCR and found that the mRNA expression pattern of
AML-1A and AML-1B was abnormal in bone marrow samples
and highly puriﬁed MM cells from patients with MM who
express high levels of MIP-1 compared with healthy controls.
Presently, it is not clear why AML-1B is not expressed in bone
marrow cells from patients with MM, how it decreases MIP-1
production, or which other genes may be affected by the
abnormal expression pattern of the AML-1 class of TFs in MM.
Further studies to address these questions should provide
valuable insights into the control of MM cell activity and novel
approaches to blocking MIP-1 expression.
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